Applied DNA Sciences Reports Q3 FY25 Financial Results: Revenue Down 36%, Focus on DNA & mRNA Manufacturing Solutions

Applied DNA Sciences reported Q3 fiscal 2025 revenue of $304k, down from $473k in Q3 2024. The company has refocused on DNA and mRNA manufacturing solutions through its subsidiary LineaRx. Monthly net cash burn from operations decreased 19% sequentially and 25% YoY. LineaRx is commercializing three technology solutions for advanced therapeutics and diagnostics.

Applied DNA Sciences (NASDAQ: APDN) reported its third-quarter fiscal 2025 financial results, highlighting a strategic shift towards DNA and mRNA manufacturing solutions through its subsidiary, LineaRx. The company's revenue decreased to $304,000 from $473,000 in the same quarter last year, while operating losses widened to $3.7 million from $3.3 million [1].

The company has been focusing on three key technologies: LineaDNA™, LineaRNAP™, and LineaIVT™. These technologies are designed for advanced therapeutics and diagnostics, and the company has seen a notable achievement with a $600,000+ follow-on order for LineaDNA [1]. Additionally, the company reported a 19% sequential reduction in monthly cash burn to $934,000, representing a 25% decrease year-over-year [1].

The strategic pivot to focus exclusively on LineaRx's DNA/mRNA technologies represents a bet on the growing biotherapeutics market, including gene therapies and mRNA applications. However, the transition from diversified revenue streams to a single business model increases execution risk in the near term [1].

Notably, Applied DNA underwent two reverse stock splits during the period, which are typically signs of financial distress and attempts to maintain Nasdaq listing requirements [1]. Despite this, the company received $723,000 from warrant exercises during the quarter and an additional $292,000 subsequently [1].

The company ended the quarter with $4.7 million in cash, providing approximately 5 months of runway at current burn rates. However, management expects further reductions in cash burn for the following quarter, which could extend this timeline [1].

In summary, Applied DNA Sciences' Q3 fiscal 2025 results reflect a company in transition, with declining revenue and continued losses. However, the strategic repositioning and reduced cash burn provide some optimism for the future.

References:
[1] https://www.stocktitan.net/news/APDN/applied-dna-reports-third-quarter-fiscal-2025-financial-vlp9e9vivwm5.html